 The background of the clinical trial is the overall aim of the World Health Organization WHO to obtain eradication of polio in the world. As part of this overall plan, inactivated polio vaccine IPV against poliovirus types 1, 2 and 3, at an affordable price, needs to become available in low resource third World countries. 